Citations

Clear

29 citation(s) found for "Sprague, S".

Control of Diabetic Diarrhea with Antibiotic Therapy
Berge, Kenneth G., Sprague, Randall G., Green, Paul A

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 17 | Issue: 6 | Pages: 385-387

10.2337/diab.17.6.385 | PMID 5652471 Get It

The ability of oral antibiotic treatment to control diabetic diarrhea was documented by a double-blind study involving a patient with this condition. When the patient was given Mysteclin-F, the diarrhea subsided promptly, only to recur when a placebo was substituted,. The erratic behavior of diabetic diarrhea is indicated, however, by the fact that a remission eventually occurred, and no further treatment was required. Although not all patients with diabetic diarrhea respond to antibiotic treatment, its trial merits consideration forthose patients who are refractory to the simpler forms of treatment.
Convocation in Toronto: An Address
Sprague, Randall G.

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 14 | Issue: 1 | Pages: 37-43

10.2337/diab.14.1.37 | PMID 14260099 Get It

The Intestinal Tract in Diabetic Diarrhea: A Pathologic Study
Berge, Kenneth G., Sprague, Randall G., Bennett, Warren A.

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 5 | Issue: 4 | Pages: 289-294

10.2337/diab.5.4.289 | PMID 13356718 Get It

Steatorrhea Complicating Diabetes Mellitus with Neuropathy: Report of Cases without Apparent External Pancreatic Insufficiency
Berge, Kenneth G., Wollaeger, Eric E., Scholz, D, Rooke, E. Douglas , Sprague, Randall G.

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 5 | Issue: 1 | Pages: 25-31

10.2337/diab.5.1.25 | PMID 13294004 Get It

Disturbances of gastrointestinal function have frequently been observed in association with diabetes mellitus. The disorders which have been reported include gastric atony and dilatation, postprandial abdominal cramping, severe constipation, and intractable diarrhea characterized by watery stools, nocturnal exacerbations and fecal incontinence. These disturbances have been attributed by many investigators to alterations in gastrointestinal motility secondary to visceral diabetic neuropathy. The purpose of the present report is to call attention to a group of patients with diabetes mellitus and neuropathy who exhibited diarrhea and steatorrhea which apparently could not be attributed to external pancreatic insufficiency.
The Effects of Adrenalectomy and of Hypophysectomy on the Degenerative Complications of Diabetes
Sprague, Randall G.

Mayo Clinic

Diabetes | December 11, 2014 | Volume: 3 | Issue: 5 | Pages: 411-412

10.2337/diab.3.5.411 | PMID 13220444 Get It

Comparative Uterotrophic Effects of Endoxifen and Tamoxifen in Ovariectomized Sprague-Dawley Rats
Schweikart, Karen, Eldridge, Sandy , Safgren, Stephanie L. , Parman, Toufan, Ames, Matthew M. , Davis, Myrtle A., Reid, Joel M. , Goetz, Matthew P. , Safgren, Stephanie L

Mayo Clinic

Toxicologic Pathology | March 26, 2014 | Volume: 42 | Issue: 8 | Pages: 1188-1196

10.1177/0192623314525688 | PMID 24670817 Get It

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen), one of the major active metabolites of tamoxifen, has substantially greater estrogen antagonist properties and antiproliferative effects in breast tumor cells than tamoxifen, a mixed estrogen agonist/antagonist. An associated risk of endometrial cancer and hyperplasia has been linked to the estrogen agonist properties of tamoxifen. We evaluated endoxifen using a classic uterotrophic effects method. Rats were given endoxifen or tamoxifen orally for 3 days. Estradiol was the positive control. Endoxifen and tamoxifen plasma levels exceeded those previously observed clinically. Uterine weight was 3-fold higher in the estradiol group than in the tamoxifen or endoxifen groups, which did not differ from vehicle controls. Tamoxifen and endoxifen caused a greater increase in luminal epithelial cell height than estradiol. Both tamoxifen and endoxifen produced an increase in the stromal BrdU labeling index (LI) that was ≤ estradiol and inversely related to dose, but did not affect luminal epithelial cell BrdU LI. As expected, estradiol increased luminal epithelial cell proliferation. These results indicate that endoxifen induces uterotrophic effects, but is less potent than estradiol in eliciting these effects. Given prior preclinical observations that endoxifen has superior antitumor activity than tamoxifen, the observations of similar uterine effects suggest that the endoxifen risk/benefit ratio may be superior to tamoxifen.
Optimized administration regimen of lopinavir for a myocardial ischaemia reperfusion study in Sprague–Dawley rats
Katayama, Minako , Jiamsripong, Panupong, Bukatina, A. E., Lombari, Theresa R, McMahon, Eileen M. , Gades, Naomi M. , Bëlohlávek, Marek

Mayo Clinic

Laboratory Animals | April 5, 2013 | Volume: 47 | Issue: 2 | Pages: 122-126

10.1177/0023677213476864 | PMID 23563365 Get It

Pharmacokinetics of drugs may differ between small and large mammals (including humans); therefore, drug testing in animal models must be carefully designed. Sprague–Dawley rats were used in cardiac experiments, during which the lopinavir concentration in serum had to match human therapeutic levels (4–10 μg/mL). Lopinavir was administered as a co-formulated drug of lopinavir and ritonavir. It was found that after a single administration of a standard human peroral dose (lopinavir 13.3 mg/kg of body weight), the serum concentration of lopinavir was only one-tenth of the target level. It remained below the minimum target level even after 10-fold the standard dose was administered. After initial pilot tests, a dose escalation study was conducted with oral doses 10- and 15-fold the standard clinical dose of lopinavir (i.e. 133 and 200 mg/kg, respectively). A second administration 2 h later effectively increased and maintained higher concentrations during the experimental ischaemia and reperfusion periods. A dose-dependent increase in serum concentration of the drug was observed. Thus, the target therapeutic serum level of lopinavir in the rats was achieved by administrating 10- to 15-fold the standard human dose twice, separated by a 2 h interval.
The neuropathies associated with diabetes mellitus
Mulder, Donald W., Lambert, Edward H. , Bastron, James A., Sprague, Randall G.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 11 | Issue: 4 | Pages: 275-275

10.1212/wnl.11.4.275 | PMID 13773672 Get It

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
Assche, Gert Van , Sandborn, William J. , Feagan, Brian G. , Salzberg, Bruce, Silvers, David, Monroe, Paul S., Pandak, William M. , Anderson, Frank , Valentine, John F. , Wild, Gary , Geenen, Daniel J., Sprague, Rebecca , Targan, Stephan R. , Rutgeerts, P., Vexler, Vladimir, Young, David M., Shames, Richard

Mayo Clinic

Gut | April 7, 2006 | Volume: 55 | Issue: 11 | Pages: 1568-1574

10.1136/gut.2005.089854 | PMID 16603634 Get It

Background: An uncontrolled pilot study demonstrated that daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), might be effective for the treatment of active ulcerative colitis. Methods: A randomised, double blind, placebo controlled trial was conducted to evaluate the efficacy of daclizumab induction therapy in patients with active ulcerative colitis. A total of 159 patients with moderate ulcerative colitis were randomised to receive induction therapy with daclizumab 1 mg/kg intravenously at weeks 0 and 4, or 2 mg/kg intravenously at weeks 0, 2, 4, and 6, or placebo. The primary end point was induction of remission at week 8. Remission was defined as a Mayo score of 0 on both endoscopy and rectal bleeding components and a score of 0 or 1 on stool frequency and physician’s global assessment components. Response was defined as a decrease from baseline in the Mayo score of at least 3 points. Results: Two per cent of patients receiving daclizumab 1 mg/kg (p = 0.11 v placebo) and 7% of patients receiving 2 mg/kg (p = 0.73) were in remission at week 8, compared with 10% of those who received placebo. Response occurred at week 8 in 25% of patients receiving daclizumab 1 mg/kg (p = 0.04) and in 33% of patients receiving 2 mg/kg (p = 0.30) versus 44% of those receiving placebo. Daclizumab was well tolerated. The most frequently reported adverse events in daclizumab treated patients compared with placebo treated patients were nasopharyngitis (14.6%) and pyrexia (10.7%). Conclusion: Patients with moderate ulcerative colitis who are treated with daclizumab are not more likely to be in remission or response at eight weeks than patients treated with placebo.